Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis

BACKGROUND: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are immune therapies that have shown great promise in the treatment of multiple cancers. However, immune-related adverse events of PD-1 and PD-L1 inhibitors may limit their use in non-small cell lung cancer (NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Honglin, Han, Deting, Feng, Xiaoteng, Yu, Wenjun, Xu, Tongtong, Ma, Tao, Song, Lucheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593004/
https://www.ncbi.nlm.nih.gov/pubmed/32769920
http://dx.doi.org/10.1097/MD.0000000000021613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593004/
https://www.ncbi.nlm.nih.gov/pubmed/32769920
http://dx.doi.org/10.1097/MD.0000000000021613

Ejemplares similares